China's Grip on US Drug Supply Sparks Alarm Over Shortages

The US pharmaceutical industry's deepening entanglement with China's supply ecosystem poses an existential threat to medicine availability. In a compelling analysis by The National Interest, experts dissect the perils using Heparin, a vital anticoagulant, as the canary in the coal mine. Seventy percent of America's Heparin supply chains back to China, where domestic US facilities—now Chinese-owned—stand as the last line. No independent, large-scale production remains stateside, a vulnerability exposed brutally in 2008 when adulterated Chinese Heparin claimed 149 lives across 11 nations. The contamination, linked to a Jiangsu facility, evaded accountability as Beijing stonewalled FDA investigators. Rather than pivot, US firms retreated further, ceding ground and intensifying reliance amid shrinking global sources. 'Production origins are contracting, not expanding,' the report notes, bolstering Chinese API makers while eroding Washington's leverage. China's strategic blueprint, the 15th Five-Year Plan, eyes biomanufacturing dominance, surging its high-control product list to 315. Past leverage in commodities like rare earths demonstrates Beijing's playbook: pressure partners, inflate costs. Heparin disruptions from quality lapses or tensions would cripple dialysis care, among others. Enter the 2025 SAPIR initiative, aiming to stockpile APIs for essentials with a domestic bent. But tech-focused programs overlook biologics like Heparin, underscoring gaps. As geopolitical frictions simmer, reshoring production emerges as the urgent imperative to safeguard public health.